BioCentury
ARTICLE | Company News

Novartis loses bid to stop German gliptin review

May 16, 2013 12:56 AM UTC

A German court on Wednesday dismissed a suit from Novartis AG (NYSE:NVS; SIX:NOVN) seeking to block the assessment of the pharma's Type II diabetes drugs in the dipeptidyl peptidase-4 (DPP-4) inhibitor (gliptin) class. Preliminary assessments on the drugs -- Galvus vildagliptin and Icandra vildagliptin/metformin -- are expected from the Institute for Quality and Efficiency in Healthcare (IQWiG) in July. ...